Effective 1/30/2025: Texas Medicaid Preferred Drug List Updates
Date: 01/06/25
The Texas Health and Human Services Commission (HHSC) will publish the semi-annual update of the Texas Medicaid Preferred Drug List (PDL) (PDF) on Thursday, January 30, 2025. The update will be based on changes presented at the Vendor Drug Program (VDP) Drug Utilization Review (DUR) Board meetings in July 2024 and October 2024. Superior HealthPlan follows the Texas Medicaid Vendor Drug Formulary and the PDL.
The tables below summarize some of the anticipated noteworthy changes from the July 2024 and October 2024 DUR meetings.
DRUG CLASS | DRUG NAME | CURRENT | STATUS CHANGE ON 1/30/24 |
Calcium Channel Blockers | Nifedipine Capsule (Oral) | Non-Preferred | Preferred |
Norvasc Tablet (Oral) | Non-Preferred | Preferred | |
Glucorticoids, Inhaled | Fluticasone Propionate (AG) (Inhalation) | Not Rated | Non-Preferred |
Immunosuppressives, Oral/SQ | Cellcept Suspension (Oral) | Non-Preferred | Preferred |
Sirolimus Solution & Tablet (Oral) | Non-Preferred | Preferred | |
Ulcerative Colitis Agents | Apriso (Oral) | Non-Preferred | Preferred |
Dipentum (Oral) | Non-Preferred | Preferred | |
Lialda (Oral) | Preferred | Non-Preferred | |
Mesalamine (Lialda) (Oral) | Non-Preferred | Preferred | |
Sfrowasa (Rectal) | Non-Preferred | Preferred | |
Uceris (Oral) | Non-Preferred | Preferred | |
Cytokine & CAM Antagonist | Simlandi (Subcutaneous) | Not Rated | Non-Preferred |
Spevigo (Subcutaneous) | Not Rated | Non-Preferred | |
Tyenne (Subcutaneous) | Not Rated | Non-Preferred | |
Adalimumab-adbm (All SQ formulations) | Not Rated | Non-Preferred | |
Cyltezo (All SQ formulations) | Not Rated | Non-Preferred | |
Omvoh PFS (Subcutaneous) | Not Rated | Non-Preferred | |
Rinvoq LQ Solution (Oral) | Not Rated | Non-Preferred | |
PAH Agents, Oral and Inhaled | Opsynvi (Oral) | Not Rated | Non-Preferred |
Antivirals, Topical | Docosanol OTC (Topical) | Non-Preferred | Preferred |
Xerese (Topical) | Non-Preferred | Preferred | |
GI Motility, Chronic | Lotronex (Oral) | Non-Preferred | Preferred |
Trulance (Oral) | Non-Preferred | Preferred | |
Hypoglycemics, Incretin Mimetics/Enhancers | Sitagliptin Tablet (Oral) | Not Rated | Non-Preferred |
Sitagliptin/Metformin Tablet (Oral) | Not Rated | Non-Preferred | |
Zituvio Tablet (Oral) | Not Rated | Non-Preferred | |
Hypoglycemics, Insulin and Related | Fiasp (All SQ formulations) | Non-Preferred | Preferred |
Levemir (All SQ formulations) | Preferred | Non-Preferred | |
Novolin N Flexpen (Subcutaneous) | Non-Preferred | Preferred | |
Toujeo (All SQ formulations) | Non-Preferred | Preferred | |
Hypoglycemics, SGLT2 | Invokamet (XR) (Oral) | Preferred | Non-Preferred |
Invokana (Oral) | Preferred | Non-Preferred | |
Synjardy XR (Oral) | Non-Preferred | Preferred | |
Hypoglycemics, TZD | Duetact Tablet (Oral) | Non-Preferred | Preferred |
Opiate Dependence Treatments | Rextovy Spray (Nasal) | Not Rated | Preferred |
Immunomodulators, Atopic Dermatitis | Adbry Autoinjector (Subcutaneous) | Not Rated | Non-Preferred |
Zoryve Cream (All topical formulations) | Not Rated | Non-Preferred | |
Immunomodulators, Asthma | Xolair Autoinjector (Subcutaneous) | Not Rated | Preferred |
Angiotensin Modulators | Entresto Sprinkle Capsule (Oral) | Not Rated | Non-Preferred |
Immunosuppressives, Oral/SQ | Myhibbin Suspension (Oral) | Not Rated | Non-Preferred |
Oncology, Oral – Other | Ojemda Suspension (Oral) | Not Rated | Preferred |
Ojemda Tablet (Oral) | Not Rated | Preferred |
Please note: The tables are not the complete list of changes. Please reference the Texas Medicaid PDL (PDF) for a complete list of recommended medications or visit DUR Board webpage on the Texas Vendor Drug website for all decisions.